Hims & Hers Health/$HIMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hims & Hers Health
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Ticker
$HIMS
Sector
Primary listing
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
1,637
ISIN
US4330001060
Website
HIMS Metrics
BasicAdvanced
$11B
73.73
$0.68
2.10
-
Price and volume
Market cap
$11B
Beta
2.1
52-week high
$72.98
52-week low
$13.47
Average daily volume
45M
Financial strength
Current ratio
1.594
Quick ratio
1.176
Long term debt to equity
10.86
Total debt to equity
11.54
Profitability
EBITDA (TTM)
137.678
Gross margin (TTM)
77.04%
Net profit margin (TTM)
9.21%
Operating margin (TTM)
6.47%
Effective tax rate (TTM)
-37.22%
Revenue per employee (TTM)
$1,090,000
Management effectiveness
Return on assets (TTM)
10.77%
Return on equity (TTM)
36.79%
Valuation
Price to earnings (TTM)
73.732
Price to revenue (TTM)
6.144
Price to book
20.46
Price to tangible book (TTM)
28.96
Price to free cash flow (TTM)
46.352
Free cash flow yield (TTM)
2.16%
Free cash flow per share (TTM)
108.45%
Growth
Revenue change (TTM)
85.99%
Earnings per share change (TTM)
-6,216.96%
3-year revenue growth (CAGR)
77.17%
3-year earnings per share growth (CAGR)
23.18%
What the Analysts think about HIMS
Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.
Bulls say / Bears say
Hims & Hers Health's acquisition of UK-based startup Zava expands its international presence, particularly in Germany, France, and Ireland, potentially increasing its customer base and revenue streams. (reuters.com)
The company's strong Q1 results, with revenue growing 46% to $278.2 million and a 41% increase in subscribers to 1.71 million, indicate robust business performance and customer acquisition. (fool.com)
Hims & Hers' acquisition of Trybe Labs enables at-home testing services, enhancing personalized treatments and supporting early disease detection, which could attract more customers seeking convenient healthcare solutions. (nasdaq.com)
Novo Nordisk terminated its partnership with Hims & Hers due to allegations of deceptive marketing and mass sales of compounded versions of its weight-loss drug, Wegovy, leading to a 32% drop in Hims & Hers' shares. (ft.com)
The FDA's decision to end the emergency measure allowing pharmacies to compound cheaper versions of weight-loss drugs like Wegovy and Zepbound may negatively impact Hims & Hers' revenue from these products. (ft.com)
Eli Lilly's decision to sell its weight-loss drug Zepbound at a 50% discount through its direct-to-consumer website poses a competitive threat to Hims & Hers' compounded versions of similar drugs. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
HIMS Financial Performance
Revenues and expenses
HIMS Earnings Performance
Company profitability
HIMS News
AllArticlesVideos
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman
GlobeNewsWire·2 hours ago
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
GlobeNewsWire·2 hours ago
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS
GlobeNewsWire·15 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hims & Hers Health stock?
Hims & Hers Health (HIMS) has a market cap of $11B as of July 11, 2025.
What is the P/E ratio for Hims & Hers Health stock?
The price to earnings (P/E) ratio for Hims & Hers Health (HIMS) stock is 73.73 as of July 11, 2025.
Does Hims & Hers Health stock pay dividends?
No, Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Hims & Hers Health dividend payment date?
Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Hims & Hers Health?
Hims & Hers Health (HIMS) has a beta rating of 2.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.